Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Victoza release date?

See the DrugPatentWatch profile for Victoza

When was Victoza first released (approved/marketed)?

Victoza (liraglutide) was first approved for use in the European Union on 30 January 2009 [1]. It then had a U.S. release (FDA approval) on 25 January 2010 [2].

What do people mean by “release date” for Victoza?

Searches for “release date” usually refer to one of these:
- Regulatory approval date (when the drug is officially approved).
- Time it reached the market (often close to approval, but can vary by country and rollout).

The dates above are the drug’s key regulatory approval milestones in the EU and U.S. [1][2].

How does this relate to patents and exclusivity?

If you’re tracking “release” to estimate when competition might enter (e.g., generics or other GLP-1 products), patent and exclusivity timelines can differ by country and by patent term. DrugPatentWatch.com tracks related patent details and can be a useful place to check [3].

Sources

  1. European Medicines Agency (EMA) – Victoza EPAR (authorisation date 30 Jan 2009)
  2. FDA – Victoza (liraglutide) approval (25 Jan 2010)
  3. DrugPatentWatch.com – Victoza (liraglutide) patent information


Other Questions About Victoza :

Victoza insulin price? Victoza drug class? Victoza generic name? Victoza ndc? Buy generic victoza? Victoza tablet? Victoza liraglutide?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided AI response does not evaluate specific FDA label content against the user’s claims. Instead, it states the claims are “absent_from_the_label” due to missing exact claim wording, but the user’s claim text was already provided. No FDA-approved prescribing information content was cited to support “absent_from_the_label,” and the evaluation does not align with the supplied label excerpts.


Category Scores

Indication
0
Poor

Accurate Statements

No specific medical claim beyond the provided indications/limitations/warnings is explicitly matched to label content in the label excerpts shown.
The supplied label excerpts contain only Indications/Limitations and a thyroid C-cell tumors warning/contraindication. They do not contain approval-date statements.

Unsupported Statements

“The requested claim cannot be matched to the FDA label sections shown.”
The user’s claim text was provided, but the response incorrectly frames evaluation as impossible due to missing exact claim wording; the claim is explicit and can be checked for presence in the provided label excerpts. The issue is not missing wording, but that the approval-date information is not present in the excerpts.
The evaluation status is “absent_from_the_label” with rationale that only indicates sections shown and therefore cannot match the claim.
The response does not accurately ground the “absent_from_the_label” conclusion in the actual provided excerpts; it instead centers on procedural inability (“no specific medical claim was provided”) despite claim text being present.

Contradictions


Important Omissions

A direct check stating that the provided label excerpts do not include any EU approval date or any U.S. FDA approval date for Victoza (liraglutide).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The claims evaluated are about approval dates and do not relate to dosing/safety. However, the evaluation process shown is unreliable due to incorrect handling of the provided claim text.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Mischaracterizes the reason evaluation cannot be performed (claims were provided) and does not directly and correctly map the claim text to the presence/absence within the supplied label excerpts.

Suggested Improvement
Directly state whether the provided label excerpts contain EU and/or U.S. approval dates. If not present, label the claims as “absent_from_the_label” based on the excerpt contents, without claiming that the claim wording was missing.

Drug Brand Mention Assessment

Branding Score
32
Visibility
33
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Victoza (liraglutide) was first approved for use in the European Union on 30 January 2009.


Core Claims
  • Victoza (liraglutide) was first approved for use in the European Union on 30 January 2009.
  • Victoza had a U.S. release (FDA approval) on 25 January 2010.
Differentiators
  • Defines “release date” as regulatory approval date and time it reached the market.
  • States the key regulatory approval milestones in the EU and U.S.

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 29%
50 # No
FDA 16%
50 # No
EMA 16%
50 # No